Free Trial
NASDAQ:TRAW

Traws Pharma Q1 2024 Earnings Report

Traws Pharma logo
$1.63 -0.06 (-3.55%)
Closing price 04:00 PM Eastern
Extended Trading
$1.67 +0.04 (+2.45%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Traws Pharma EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.24
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Traws Pharma Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$0.06 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Traws Pharma Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 16, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Traws Pharma's Q2 2025 earnings is scheduled for Thursday, August 21, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Traws Pharma Earnings Headlines

TRAW - Traws Pharma Inc Sustainability - Morningstar
Elon Just Fired the IRS Agents Targeting Your Savings
Elon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regain control, one overlooked IRS “backdoor” still allows retirement savers to protect their wealth — penalty-free and tax-free. A free 2025 guide reveals how to use it before it’s too late.
See More Traws Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Traws Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Traws Pharma and other key companies, straight to your email.

About Traws Pharma

Traws Pharma (NASDAQ:TRAW), a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

View Traws Pharma Profile

More Earnings Resources from MarketBeat